C‑reactive protein and cardiovascular disease: From animal studies to the clinic (Review)
- Authors:
- Yu Fu
- Yi Wu
- Enqi Liu
-
Affiliations: MOE Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Research Institute of Atherosclerotic Disease, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, P.R. China - Published online on: June 4, 2020 https://doi.org/10.3892/etm.2020.8840
- Pages: 1211-1219
-
Copyright: © Fu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Thomas H, Diamond J, Vieco A, Chaudhuri S, Shinnar E, Cromer S, Perel P, Mensah GA, Narula J, Johnson CO, et al: Global Atlas of Cardiovascular Disease 2000-2016: The Path to Prevention and Control. Glob Heart. 13:143–163. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Mortality GBD: Global, regional, and national age - sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 385:117–171. 2015.PubMed/NCBI View Article : Google Scholar | |
|
GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 388:1459–1544. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med. 340:115–126. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Tillett WS and Francis T Jr: Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 52:561–571. 1930.PubMed/NCBI View Article : Google Scholar | |
|
Taylor AW, Ku NO and Mortensen RF: Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-beta. J Immunol. 145:2507–2513. 1990.PubMed/NCBI | |
|
Thompson D, Pepys MB and Wood SP: The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 7:169–177. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Pepys MB and Baltz ML: Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 34:141–212. 1983.PubMed/NCBI View Article : Google Scholar | |
|
Shine B, de Beer FC and Pepys MB: Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta. 117:13–23. 1981.PubMed/NCBI View Article : Google Scholar | |
|
Pepys MB and Hirschfield GM: C-reactive protein: A critical update. J Clin Invest. 111:1805–1812. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Volanakis JE and Kaplan MH: Interaction of C-reactive protein complexes with the complement system II. Consumption of guinea pig complement by CRP complexes: Requirement for human C1q. J Immunol. 113:9–17. 1974.PubMed/NCBI | |
|
Claus DR, Siegel J, Petras K, Osmand AP and Gewurz H: Interactions of C-reactive protein with the first component of human complement. J Immunol. 119:187–192. 1977.PubMed/NCBI | |
|
Moutachakkir M, Lamrani Hanchi A, Baraou A, Boukhira A and Chellak S: Immunoanalytical characteristics of C-reactive protein and high sensitivity C-reactive protein. Ann Biol Clin (Paris). 75:225–229. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Calabrò P, Golia E and Yeh ET: CRP and the risk of atherosclerotic events. Semin Immunopathol. 31:79–94. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Koenig W: High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy. Int J Cardiol. 168:5126–5134. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, et al: Centers for Disease Control and Prevention; American Heart Association: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 107:499–511. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 107:363–369. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R and Danesh J: Emerging Risk Factors Collaboration: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet. 375:132–140. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Jousilahti P, Vartiainen E, Tuomilehto J and Puska P: Sex, age, cardiovascular risk factors, and coronary heart disease: A prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. 99:1165–1172. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature. 362:801–809. 1993.PubMed/NCBI View Article : Google Scholar | |
|
Frostegård J: Immunity, atherosclerosis and cardiovascular disease. BMC Med. 11(117)2013.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM, Cushman M, Stampfer MJ, Tracy RP and Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:973–979. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL and Pepys MB: C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 99:237–242. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR and Pepys MB: Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ. 321:199–204. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM, Hennekens CH, Buring JE and Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 342:836–843. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM: C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: Moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 49:2129–2138. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM, Rifai N, Rose L, Buring JE and Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 347:1557–1565. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Shah PK: Circulating markers of inflammation for vascular risk prediction: Are they ready for prime time. Circulation. 101:1758–1759. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ and Hack CE: C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Circulation. 100:96–102. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ and Chan L: C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 109:647–655. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Yu Q, Li Y, Wang Y, Zhao S, Yang P, Chen Y, Fan J and Liu E: C-reactive protein levels are associated with the progression of atherosclerotic lesions in rabbits. Histol Histopathol. 27:529–535. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, Kitajima S, Morimoto M, Watanabe T, Asada Y, et al: C-reactive protein in atherosclerotic lesions: Its origin and pathophysiological significance. Am J Pathol. 167:1139–1148. 2005.PubMed/NCBI View Article : Google Scholar | |
|
de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A and Pepys MB: Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J. 47:239–243. 1982.PubMed/NCBI View Article : Google Scholar | |
|
Berk BC, Weintraub WS and Alexander RW: Elevation of C-reactive protein in ‘active’ coronary artery disease. Am J Cardiol. 65:168–172. 1990.PubMed/NCBI View Article : Google Scholar | |
|
Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, Tarin C, Mas S, Ortiz A and Egido J: Animal models of cardiovascular diseases. J Biomed Biotechnol. 2011(497841)2011.PubMed/NCBI View Article : Google Scholar | |
|
Torzewski M, Waqar AB and Fan J: Animal models of C-reactive protein. Mediators Inflamm. 2014(683598)2014.PubMed/NCBI View Article : Google Scholar | |
|
Kumar S, Stecher G and Tamura K: MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol Biol Evol. 33:1870–1874. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA and Verma S: C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 107:1783–1790. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA and Pepys MB: Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 102:8309–8314. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Kovacs A, Tornvall P, Nilsson R, Tegnér J, Hamsten A and Björkegren J: Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA. 104:13768–13773. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Teupser D, Weber O, Rao TN, Sass K, Thiery J and Fehling HJ: No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J Biol Chem. 286:6272–6279. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Yu Q, Lin Y, Yang P, Wang Y, Zhao S, Yang P, Fan J and Liu E: C-reactive protein is associated with the progression of acute embolic stroke in rabbit model. J Thromb Thrombolysis. 33:301–307. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Yu Q, Liu Z, Waqar AB, Ning B, Yang X, Shiomi M, Graham MJ, Crooke RM, Liu E, Dong S, et al: Effects of antisense oligonucleotides against C-reactive protein on the development of atherosclerosis in WHHL rabbits. Mediators Inflamm. 2014(979132)2014.PubMed/NCBI View Article : Google Scholar | |
|
Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, Sabin CA, Dhillon AP and Pepys MB: Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis. 196:248–255. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Reifenberg K, Lehr HA, Baskal D, Wiese E, Schaefer SC, Black S, Samols D, Torzewski M, Lackner KJ, Husmann M, et al: Role of C-reactive protein in atherogenesis: Can the apolipoprotein E knockout mouse provide the answer? Arterioscler Thromb Vasc Biol. 25:1641–1646. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Torzewski M, Reifenberg K, Cheng F, Wiese E, Küpper I, Crain J, Lackner KJ and Bhakdi S: No effect of C-reactive protein on early atherosclerosis in LDLR-/- / human C-reactive protein transgenic mice. Thromb Haemost. 99:196–201. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Trion A, de Maat MP, Jukema JW, van der Laarse A, Maas MC, Offerman EH, Havekes LM, Szalai AJ, Princen HM and Emeis JJ: No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol. 25:1635–1640. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Koike T, Kitajima S, Yu Y, Nishijima K, Zhang J, Ozaki Y, Morimoto M, Watanabe T, Bhakdi S, Asada Y, et al: Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation. 120:2088–2094. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Pepys MB, Baltz M, Gomer K, Davies AJ and Doenhoff M: Serum amyloid P-component is an acute-phase reactant in the mouse. Nature. 278:259–261. 1979.PubMed/NCBI View Article : Google Scholar | |
|
Fan J, Kitajima S, Watanabe T, Xu J, Zhang J, Liu E and Chen YE: Rabbit models for the study of human atherosclerosis: From pathophysiological mechanisms to translational medicine. Pharmacol Ther. 146:104–119. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kushner I and Feldmann G: Control of the acute phase response Demonstration of C-reactive protein synthesis and secretion by hepatocytes during acute inflammation in the rabbit. J Exp Med. 148:466–477. 1978.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM, Rifai N, Pfeffer MA, Sacks F and Braunwald E: The Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 100:230–235. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Hutchinson WL, Koenig W, Fröhlich M, Sund M, Lowe GD and Pepys MB: Immunoradiometric assay of circulating C-reactive protein: Age-related values in the adult general population. Clin Chem. 46:934–938. 2000.PubMed/NCBI | |
|
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB and Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 350:1387–1397. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Haverkate F, Thompson SG, Pyke SD, Gallimore JR and Pepys MB: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 349:462–466. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G and Maseri A: Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 99:855–860. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM: C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart J. 19:1–3. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB and Maseri A: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 331:417–424. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA and Braunwald E: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 352:20–28. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al: JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 359:2195–2207. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC and Braunwald E: Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:839–844. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS and Gotto AM Jr: Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 344:1959–1965. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C and Ganz P: Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 352:29–38. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA and Braunwald E: Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 132:1224–1233. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al: CANTOS Trial Group: Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 377:1119–1131. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Jialal I, Devaraj S and Venugopal SK: C-reactive protein: Risk marker or mediator in atherothrombosis? Hypertension. 44:6–11. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Labarrere CA and Zaloga GP: C-reactive protein: From innocent bystander to pivotal mediator of atherosclerosis. Am J Med. 117:499–507. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Verma S, Devaraj S and Jialal I: Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 113:2135–2150; discussion 2150. 2006.PubMed/NCBI | |
|
Pasceri V, Cheng JS, Willerson JT and Yeh ET: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 103:2531–2534. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Boring L, Gosling J, Cleary M and Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:894–897. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P and Rollins BJ: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 2:275–281. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Pasceri V, Willerson JT and Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 102:2165–2168. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Qamirani E, Ren Y, Kuo L and Hein TW: C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase. Arterioscler Thromb Vasc Biol. 25:995–1001. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Devaraj S, Yun JM, Adamson G, Galvez J and Jialal I: C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res. 84:479–484. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Hein TW, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L and Jialal I: Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis. 206:61–68. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Devaraj S, Kumaresan PR and Jialal I: C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: Further evidence of endothelial dysfunction. Clin Chem. 57:1757–1761. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Venugopal SK, Devaraj S, Yuhanna I, Shaul P and Jialal I: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 106:1439–1441. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, et al: C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 109:2058–2067. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B and Mickle DA: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 105:1890–1896. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, et al: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 106:913–919. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Teoh H, Quan A, Lovren F, Wang G, Tirgari S, Szmitko PE, Szalai AJ, Ward ME and Verma S: Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis. 201:318–325. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S and Zeiher AM: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 102:1000–1006. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS, Chiariello L and Gioffrè PA: Unstable angina and elevated c-reactive protein levels predict enhanced vasoreactivity of the culprit lesion. Circulation. 104:1471–1476. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL and Connell JM: Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond). 98:531–535. 2000.PubMed/NCBI | |
|
Devaraj S, Kumaresan PR and Jialal I: Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol. 36:405–410. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Tabas I, García-Cardeña G and Owens GK: Recent insights into the cellular biology of atherosclerosis. J Cell Biol. 209:13–22. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Calabró P, Willerson JT and Yeh ET: Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 108:1930–1932. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Chistiakov DA, Orekhov AN and Bobryshev YV: Vascular smooth muscle cell in atherosclerosis. Acta Physiol (Oxf). 214:33–50. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Ryu J, Lee CW, Shin JA, Park CS, Kim JJ, Park SJ and Han KH: FcgammaRIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. Cardiovasc Res. 75:555–565. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Liu N, Liu J, Ji Y, Lu P, Wang C and Guo F: C-reactive protein induces TNF-α secretion by p38 MAPK-TLR4 signal pathway in rat vascular smooth muscle cells. Inflammation. 34:283–290. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Liu N, Liu JT, Ji YY and Lu PP: C-reactive protein triggers inflammatory responses partly via TLR4/IRF3/NF-κB signaling pathway in rat vascular smooth muscle cells. Life Sci. 87:367–374. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Cermak J, Key NS, Bach RR, Balla J, Jacob HS and Vercellotti GM: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 82:513–520. 1993.PubMed/NCBI | |
|
Nakagomi A, Freedman SB and Geczy CL: Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive prote in: Relationship with age, sex, and hormone replacement treatment. Circulation. 101:1785–1791. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Williams TN, Zhang CX, Game BA, He L and Huang Y: C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathway: An implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol. 24:61–66. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Ballou SP and Lozanski G: Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 4:361–368. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V and Torzewski J: C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 20:2094–2099. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Reynolds GD and Vance RP: C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med. 111:265–269. 1987.PubMed/NCBI | |
|
Yasojima K, Schwab C, McGeer EG and McGeer PL: Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 158:1039–1051. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Kobayashi S, Inoue N, Ohashi Y, Terashima M, Matsui K, Mori T, Fujita H, Awano K, Kobayashi K, Azumi H, et al: Interaction of oxidative stress and inflammatory response in coronary plaque instability: Important role of C-reactive protein. Arterioscler Thromb Vasc Biol. 23:1398–1404. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Seifert PS and Kazatchkine MD: The complement system in atherosclerosis. Atherosclerosis. 73:91–104. 1988.PubMed/NCBI View Article : Google Scholar | |
|
Torzewski J, Bowyer DE, Waltenberger J and Fitzsimmons C: Processes in atherogenesis: Complement activation. Atherosclerosis. 132:131–138. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Niculescu F, Rus HG and Vlaicu R: Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis. 65:1–11. 1987.PubMed/NCBI View Article : Google Scholar | |
|
Torzewski J, Torzewski M, Bowyer DE, Fröhlich M, Koenig W, Waltenberger J, Fitzsimmons C and Hombach V: C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 18:1386–1392. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, Blumenthal RS and Budoff MJ: High-sensitivity C-reactive protein and cardiovascular disease: A resolute belief or an elusive link? J Am Coll Cardiol. 62:397–408. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Bielas H, Meister-Langraf RE, Schmid JP, Barth J, Znoj H, Schnyder U, Princip M and von Känel R: C-reactive protein as a predictor of posttraumatic stress induced by acute myocardial infarction. Gen Hosp Psychiatry. 53:125–130. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L, Palmieri V, Roman M, Devereux RB, Fabsitz RR, Tracy RP, et al: C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: The Strong Heart Study. Circulation. 112:1289–1295. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Hurlimann J, Thorbecke GJ and Hochwald GM: The liver as the site of C-reactive protein formation. J Exp Med. 123:365–378. 1966.PubMed/NCBI View Article : Google Scholar | |
|
Eklund CM: Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem. 48:111–136. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Jensen HS: C-reactive protein. Ugeskr Laeger. 162:2453–2456. 2000.PubMed/NCBI(In Danish). | |
|
Deban L, Bottazzi B, Garlanda C, de la Torre YM and Mantovani A: Pentraxins: Multifunctional proteins at the interface of innate immunity and inflammation. Biofactors. 35:138–145. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Laskowitz DT, Lee DM, Schmechel D and Staats HF: Altered immune responses in apolipoprotein E-deficient mice. J Lipid Res. 41:613–620. 2000.PubMed/NCBI | |
|
Grainger DJ, Reckless J and McKilligin E: Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol. 173:6366–6375. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Li HY, Liu XL, Liu YT, Jia ZK, Filep JG, Potempa LA, Ji SR and Wu Y: Matrix sieving-enforced retrograde transcytosis regulates tissue accumulation of C-reactive protein. Cardiovasc Res. 115:440–452. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Su HX, Zhou HH, Wang MY, Cheng J, Zhang SC, Hui F, Chen XZ, Liu SH, Liu QJ, Zhu ZJ, et al: Mutations of C-reactive protein (CRP) -286 SNP, APC and p53 in colorectal cancer: Implication for a CRP-Wnt crosstalk. PLoS One. 9(e102418)2014.PubMed/NCBI View Article : Google Scholar |
